FLT3 (Phospho-Tyr842) Antibody

Catalog No: #11731

Package Size: #11731-1 50ul #11731-2 100ul




Orders: order@signalwayantibody.com Support: tech@signalwayantibody.com

Product Name	FLT3 (Phospho-Tyr842) Antibody
Host Species	Rabbit
Clonality	Polyclonal
Purification	Antibodies were produced by immunizing rabbits with synthetic phosphopeptide and KLH conjugates.
	Antibodies were purified by affinity-chromatography using epitope-specific phosphopeptide. Non-phospho
	specific antibodies were removed by chromatogramphy using non-phosphopeptide.
Applications	WB
Species Reactivity	Hu Ms
Specificity	The antibody detects endogenous levels of FLT3 only when phosphorylated at tyrosine 842.
Immunogen Type	Peptide-KLH
Immunogen Description	Peptide sequence around phosphorylation site of tyrosine 842(S-N-Y(p)-V-V) derived from Human FLT3 .
Target Name	FLT3
Modification	Phospho
Other Names	CD135; STK1; FLK-2; FLT-3;
Accession No.	Swiss-Prot#: P36888; NCBI Gene#: 2322; NCBI Protein#: NP_004110.2.
SDS-PAGE MW	170kd
Concentration	1.0mg/ml
Formulation	Rabbit IgG in phosphate buffered saline (without Mg2+ and Ca2+), pH 7.4, 150mM NaCl, 0.02% sodium azid
	and 50% glycerol.
Storage	Store at -20°C/1 year

Application Details

Western blotting: 1:500~1:1000

Images



Address: 6305 Ivy Lane, Suite 370 Greenbelt, Maryland 20770, USA http://www.sabbiotech.com

Background

FLT3 encodes a class III receptor tyrosine kinase that regulates hematopoiesis. The receptor consists of an extracellular domain composed of five immunoglobulin-like domains, one transmembrane region, and a cytoplasmic kinase domain split into two parts by a kinase-insert domain. The receptor is activated by binding of the fms-related tyrosine kinase 3 ligand to the extracellular domain, which induces homodimer formation in the plasma membrane leading to autophosphorylation of the receptor. The activated receptor kinase subsequently phosphorylates and activates multiple cytoplasmic effector molecules in pathways involved in apoptosis, proliferation, and differentiation of hematopoietic cells in bone marrow. Mutations that result in the constitutive activation of this receptor result in acute myeloid leukemia and acute lymphoblastic leukemia. Small D., Proc. Natl. Acad. Sci. U.S.A. 91:459-463(1994).

oniai 2., 1100. Nati. 7 (000. 001. 0.0.7). 01.400 40

Rosnet O., Blood 82:1110-1119(1993).

Rosnet O., Genomics 9:380-385(1991).

Note: This product is for in vitro research use only and is not intended for use in humans or animals.